US2016024014A1PendingUtilityA1
5ht2c receptor modulators
Est. expiryApr 12, 2022(expired)· nominal 20-yr term from priority
A61P 5/24A61P 3/06A61P 9/00A61P 43/00A61P 9/10A61P 9/12A61P 3/10A61P 25/14A61P 25/08A61P 25/24A61P 25/30A61P 25/00A61P 25/22A61P 25/06A61P 25/36A61P 25/04A61P 3/00A61P 27/02A61P 27/12A61P 25/18A61P 25/28A61P 3/04A61P 27/06A61P 25/32A61P 25/20A61P 35/00A61P 1/16C07D 409/04A61P 15/00A61K 9/20A61P 11/16A61K 31/55A61P 11/00C07D 223/16A61P 13/12A61P 13/02A61P 1/04C07D 491/04C07D 403/04A61P 13/00A61P 15/08A61P 15/10A61P 1/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel compounds of Formula (I): which act as 5HT 2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Claims
exact text as granted — not AI-modified1 .- 12 . (canceled)
13 . A mixture of enantiomers of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.